SEATTLE, Washington, United States — October 27, 2026
Nautilus Biotechnology, Inc., a life sciences company developing technologies for high-resolution protein analysis, announced its participation in the SEEDS consortium, a four-year, multidisciplinary research initiative awarded up to $51.7 million by the Advanced Research Projects Agency for Health (ARPA-H). Co-led by the Buck Institute for Research on Aging and Georgetown University, SEEDS aims to understand how intrinsically disordered proteins change shape, misfold and aggregate during disease development, with the goal of enabling earlier diagnostics and new therapeutic approaches. Nautilus expects to receive up to $6 million over the program’s duration to apply its Voyager™ Platform to measure proteoforms, the distinct molecular forms of proteins that can influence biological function. Initial research will focus on tau, a protein associated with Alzheimer’s disease, and EWS::FLI1, a fusion protein implicated in Ewing sarcoma. The consortium plans to combine experimental protein measurements with artificial intelligence (AI) and computational modeling to predict how specific proteoforms contribute to disease-related protein aggregation and identify potential opportunities for earlier intervention.
SEEDS Consortium Targets Early Mechanisms of Protein Misfolding
Protein dysregulation, misfolding and aggregation are implicated in a range of diseases, including neurodegenerative disorders and cancer. The SEEDS consortium aims to investigate intrinsically disordered proteins, which contain regions that do not maintain a single stable three-dimensional structure and can adopt different conformations under varying conditions. These dynamic properties make such proteins difficult to characterize and can complicate the development of treatments designed to bind specific molecular structures. By examining the relationship between protein sequences, environmental conditions and structural behavior, researchers aim to identify the molecular events that precede harmful aggregation and irreversible tissue damage. The program is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) initiative, which focuses on understanding and influencing the earliest stages of protein dysfunction. Within SEEDS, Nautilus will contribute large-scale proteoform measurements to help researchers investigate how individual protein forms relate to disease processes. The project is intended to support the development of predictive models and, ultimately, diagnostic and therapeutic strategies, although any resulting clinical applications will require further research and validation.
Voyager Platform to Generate High-Resolution Proteoform Data for AI Models
Nautilus will use its Voyager Platform and proprietary Iterative Mapping method to analyze intact proteins and distinguish different proteoforms at the single-molecule level. The platform is designed to measure large numbers of individual protein molecules and record their distinct probe-binding patterns across multiple measurement cycles. Machine learning algorithms can then interpret these patterns to quantify proteins and their molecular forms, generating structured datasets for downstream biological analysis. Within SEEDS, the resulting data will initially support research into tau and EWS::FLI1, with the potential to expand to additional intrinsically disordered proteins. Researchers intend to use these datasets to train AI models that predict how proteoforms influence protein conformations and aggregation. Nautilus expects the work to contribute to a broader understanding of the molecular mechanisms driving Alzheimer’s disease and Ewing sarcoma. The company’s participation also represents the first application of its Iterative Mapping approach to a pediatric cancer research program. The consortium’s findings could help guide future research into disease detection and treatment, but the platform’s ability to produce clinically useful diagnostics or therapeutics has yet to be established.
Advertisement
Nautilus Expands Proteomics Research and Collaborative Development
Nautilus’ involvement in SEEDS builds on ongoing collaborations and technology-development activities. A Voyager Platform field-evaluation unit at the Buck Institute for Research on Aging has been generating tau proteoform data since early 2025. The company also initiated its Iterative Mapping Early Access Program earlier in 2026 to broaden access to the technology ahead of a planned Voyager Platform shipment in mid-2027. In addition, Nautilus reported peer-reviewed validation of its Iterative Mapping method in Nature Methods and a collaboration with the Michael J. Fox Foundation and Weill Cornell Medicine-Qatar to develop a proteoform assay for alpha-synuclein, a protein associated with Parkinson’s disease. The company expects to add proteoform assays on an ongoing basis, with approximately 20 anticipated by mid-2028. Nautilus believes that scalable, high-resolution protein measurements could improve researchers’ ability to investigate biological mechanisms that are difficult to capture using conventional approaches. Through SEEDS, the company will work alongside academic and computational research teams to connect molecular measurements with disease modeling. The program is funded in part by ARPA-H, and its scientific findings are intended to advance research into protein dysfunction rather than represent established clinical diagnostic or treatment methods.
Source:Nautilus Biotechnology, Press release
